Actinogen Medical Limited (ACW.AX)
AUD 0.03
(0.0%)
AUD 0.03
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -13.04 Million AUD | -21.32% |
| 2023 | -10.75 Million AUD | -13.21% |
| 2022 | -9.49 Million AUD | -142.59% |
| 2021 | -3.91 Million AUD | 26.55% |
| 2020 | -5.33 Million AUD | 46.09% |
| 2019 | -9.88 Million AUD | -58.7% |
| 2018 | -6.23 Million AUD | -95.3% |
| 2017 | -3.19 Million AUD | 12.2% |
| 2016 | -3.63 Million AUD | 33.09% |
| 2015 | -5.43 Million AUD | -1133.7% |
| 2014 | -440.22 Thousand AUD | -167.35% |
| 2013 | -164.66 Thousand AUD | 89.23% |
| 2012 | -1.52 Million AUD | -105.98% |
| 2011 | -742.38 Thousand AUD | -0.67% |
| 2010 | -737.47 Thousand AUD | 20.44% |
| 2009 | -926.94 Thousand AUD | -112.77% |
| 2008 | -435.65 Thousand AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 FY | -13.04 Million AUD | -21.32% |
| 2024 Q2 | -11.55 Million AUD | 0.0% |
| 2024 Q4 | -1.48 Million AUD | 0.0% |
| 2023 Q2 | -7.43 Million AUD | 0.0% |
| 2023 FY | -10.75 Million AUD | -13.21% |
| 2023 Q4 | -3.31 Million AUD | 0.0% |
| 2022 Q2 | -5.79 Million AUD | 0.0% |
| 2022 FY | -9.49 Million AUD | -142.59% |
| 2022 Q4 | -3.7 Million AUD | 0.0% |
| 2021 Q4 | -1.55 Million AUD | 0.0% |
| 2021 Q2 | -2.35 Million AUD | 0.0% |
| 2021 FY | -3.91 Million AUD | 26.55% |
| 2020 Q4 | -1.29 Million AUD | 0.0% |
| 2020 FY | -5.33 Million AUD | 46.09% |
| 2020 Q2 | -4.04 Million AUD | 0.0% |
| 2019 Q4 | -2.75 Million AUD | 0.0% |
| 2019 FY | -9.88 Million AUD | -58.7% |
| 2019 Q2 | -7.13 Million AUD | 0.0% |
| 2018 Q2 | -3.62 Million AUD | 0.0% |
| 2018 FY | -6.23 Million AUD | -95.3% |
| 2018 Q4 | -2.6 Million AUD | 0.0% |
| 2017 Q2 | -1.85 Million AUD | 0.0% |
| 2017 FY | -3.19 Million AUD | 12.2% |
| 2017 Q4 | -1.33 Million AUD | 0.0% |
| 2016 Q2 | -1.16 Million AUD | 0.0% |
| 2016 Q4 | -2.46 Million AUD | 0.0% |
| 2016 FY | -3.63 Million AUD | 33.09% |
| 2015 Q4 | -4.2 Million AUD | 0.0% |
| 2015 FY | -5.43 Million AUD | -1133.7% |
| 2015 Q2 | -1.22 Million AUD | 0.0% |
| 2014 FY | -440.22 Thousand AUD | -167.35% |
| 2014 Q4 | -286.98 Thousand AUD | 0.0% |
| 2014 Q2 | -153.24 Thousand AUD | 0.0% |
| 2013 FY | -164.66 Thousand AUD | 89.23% |
| 2013 Q4 | -146.75 Thousand AUD | -256.5% |
| 2013 Q3 | -41.16 Thousand AUD | -129.87% |
| 2013 Q2 | -17.9 Thousand AUD | 95.32% |
| 2013 Q1 | -382.28 Thousand AUD | 0.0% |
| 2012 Q4 | -382.28 Thousand AUD | 0.0% |
| 2012 Q1 | -185.59 Thousand AUD | 0.0% |
| 2012 Q2 | -382.28 Thousand AUD | -105.98% |
| 2012 FY | -1.52 Million AUD | -105.98% |
| 2012 Q3 | -382.28 Thousand AUD | 0.0% |
| 2011 Q3 | -185.59 Thousand AUD | 0.0% |
| 2011 FY | -742.38 Thousand AUD | -0.67% |
| 2011 Q4 | -185.59 Thousand AUD | 0.0% |
| 2011 Q2 | -185.59 Thousand AUD | -0.67% |
| 2011 Q1 | -184.36 Thousand AUD | 0.0% |
| 2010 Q1 | -231.73 Thousand AUD | 0.0% |
| 2010 FY | -737.47 Thousand AUD | 20.44% |
| 2010 Q4 | -184.36 Thousand AUD | 0.0% |
| 2010 Q3 | -184.36 Thousand AUD | 0.0% |
| 2010 Q2 | -184.36 Thousand AUD | 20.44% |
| 2009 FY | -926.94 Thousand AUD | -112.77% |
| 2009 Q1 | -108.91 Thousand AUD | 0.0% |
| 2009 Q2 | -231.73 Thousand AUD | -112.77% |
| 2009 Q3 | -231.73 Thousand AUD | 0.0% |
| 2009 Q4 | -231.73 Thousand AUD | 0.0% |
| 2008 FY | -435.65 Thousand AUD | 0.0% |
| 2008 Q4 | -108.91 Thousand AUD | 0.0% |
| 2008 Q3 | -108.91 Thousand AUD | 0.0% |
| 2008 Q2 | -108.91 Thousand AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AdAlta Limited | -5.38 Million AUD | -142.402% |
| Acrux Limited | -5.8 Million AUD | -124.901% |
| AnteoTech Limited | -8.88 Million AUD | -46.887% |
| Argenica Therapeutics Limited | -5.47 Million AUD | -138.057% |
| Arovella Therapeutics Limited | -8.74 Million AUD | -49.145% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -798.836% |
| Alterity Therapeutics Limited | -19.12 Million AUD | 31.789% |
| Amplia Therapeutics Limited | -4.5 Million AUD | -189.651% |
| Avecho Biotechnology Limited | -3.43 Million AUD | -279.574% |
| Bio-Gene Technology Limited | -2.4 Million AUD | -441.441% |
| Biome Australia Limited | -1.67 Million AUD | -681.0% |
| Biotron Limited | -3.43 Million AUD | -279.578% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | 5.951% |
| BTC Health Limited | 1.05 Million AUD | 1336.089% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | -4.106% |
| CSL Limited | 2.64 Billion AUD | 100.494% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 69.18% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 136.604% |
| Cynata Therapeutics Limited | -9.74 Million AUD | -33.86% |
| Dimerix Limited | -17.07 Million AUD | 23.606% |
| EZZ Life Science Holdings Limited | 6.96 Million AUD | 287.297% |
| Hexima Limited | -933.87 Thousand AUD | -1296.794% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | -355.406% |
| Immuron Limited | -6.93 Million AUD | -88.04% |
| Immutep Limited | -39.89 Million AUD | 67.305% |
| Imugene Limited | -149.68 Million AUD | 91.285% |
| Invex Therapeutics Ltd | -1.64 Million AUD | -694.507% |
| Memphasys Limited | -4.44 Million AUD | -193.656% |
| Nanollose Limited | -1.15 Million AUD | -1027.859% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 108.304% |
| Noxopharm Limited | -3.57 Million AUD | -264.557% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 4123.405% |
| Nyrada Inc. | -1.38 Million AUD | -840.992% |
| Orthocell Limited | -7.18 Million AUD | -81.651% |
| PharmAust Limited | -9.03 Million AUD | -44.417% |
| Patrys Limited | -3.53 Million AUD | -268.571% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 77.76% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | -104.577% |
| Prescient Therapeutics Limited | -8.23 Million AUD | -58.342% |
| PYC Therapeutics Limited | -37.72 Million AUD | 65.423% |
| Race Oncology Limited | -13.81 Million AUD | 5.608% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 72.796% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | 26.144% |
| Starpharma Holdings Limited | -8.16 Million AUD | -59.759% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | 350.322% |
| Tissue Repair Ltd | -4.13 Million AUD | -215.224% |
| Zelira Therapeutics Limited | -36.56 Million AUD | 64.33% |